Host-Directed TB Therapy: New Approaches (UH2/UH3)

The summary for the Host-Directed TB Therapy: New Approaches (UH2/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Host-Directed TB Therapy: New Approaches (UH2/UH3): The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for support of preclinical evaluation, planning for and conduct of proof-of-concept clinical studies for Mycobacterium tuberculosis (TB) treatment that will be applicable in the context of HIV co-infection using host-directed agents already approved for clinical use or in late-stage clinical trials for other conditions. Host-directed therapies (HDT) for TB that may also have activity against HIV, either directly or by enhancing immunologic reactions, are of particular interest.

Funds from the NIH will be made available through the UH2/UH3 cooperative agreement award mechanism. The initial UH2 award (up to two years) will support the development of critical preclinical data, development of study partnerships, and development of the proof-of-concept (POC) trial protocol and all supporting plans and documentation. Once UH2 pre-clinical and clinical milestones have been met, the UH3 award (up to 3 years) may be made to support the planned POC clinical trial.

Federal Grant Title:	Host-Directed TB Therapy: New Approaches (UH2/UH3)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AI-14-058
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.855, 93.856
CFDA Descriptions:	Allergy, Immunology and Transplantation Research; Microbiology and Infectious Diseases Research
Current Application Deadline:	Mar 25, 2015
Original Application Deadline:	Mar 25, 2015
Posted Date:	November 12th, 2014
Creation Date:	Nov 12, 2014
Archive Date:	Apr 25, 2015
Total Program Funding:	$2,900,000
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Independent school districts
Private institutions of higher education
Small businesses
County governments
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled "Additional Information on Eligibility" for clarification)
City or township governments
Public housing authorities/Indian housing authorities
State governments
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-14-058.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed); • Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Anti...; • Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed); • Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of H...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...